{'fraction_non_alphanumeric': 0.03089321692411014, 'fraction_numerical': 0.02216252518468771, 'mean_word_length': 5.45021645021645, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The association of isoprostane levels with cardiovascular disease risk factors in Iraqi women with polycystic ovary syndrome

The current study emphasis assay the association of 8-Isoprostane levels with cardiovascular disease risk factors in polycystic ovary syndrome patients, which is conceder as a current endocrine metabolic disorder that uncovers many serious rates outcomes to female good health, inclusively terrible ratio of infertility. This study including a total of 90 women divided into two groups (50 PCOS patients and 40 healthy controls). Homeostasis model assessment (HOMA-IR), lipid parameters, atherogenic index of plasma (AIP) as well as anthropometric measurements were measured. The level of 8-Isoprostane in serum was measured by a commercially available ELISA kit. The level of 8-Isoprostane was no significantly higher in women with polycystic ovary syndrome (61.97±51.86 pg/mL) compared with the healthy control group (52.44±28.49 pg/mL) (p˃0.05). There were significantly higher in the mean of insulin, homeostatic model assessment for insulin resistance, triglycerides and atherogenic index of plasma in polycystic ovary syndrome patients than the control group (p˂0.05). There was no correlation between 8Isoprostane with any parameter in patients with polycystic ovary syndrome as showed the Pearson correlation analyses. In conclusion, increased levels of serum 8-Isoprostane are not associated with elevated CV risk in women with polycystic ovary syndrome.